2.6 Vaccine formulations and vaccination experiments
The vaccines to be applied in mice were formulated with: (i) 0.5 µg VLPs in PBS (VLPs); (ii) 0.5 µg VLPs in PBS mixed with 6 µl ISPA (VLPs-ISPA) or (iii) 0.5 µg VLPs in PBS mixed with CA (VLPs-CA), in a final volume of 0.1 ml/dose. BALB/c mice were s.c. immunized at day 0 and 21 with: (i) VLPs (n=5); (ii) VLPs-ISPA (n=5); (iii) VLPs-CA (n= 5); (iv) Commercial Vaccine (C+) (n=5); (v) 6 µl ISPA (n= 2); (vi) (CA) (n= 2) or (vii) PBS (n= 2). Mice were challenged at 36 dpv as described in 2.4. The commercial vaccine consisted in a water-in-oil single emulsion containing O1/Campos/Brazil/58, A24/Cruzeiro/Brazil/55, C3/Indaial/Brazil/71 and A/Argentina/2001 iFMDV and was provided by Biogénesis Bagó S.A.